2020
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal Of Clinical Oncology 2020, 38: 1284-1292. PMID: 32125937, PMCID: PMC7164489, DOI: 10.1200/jco.19.00510.Peer-Reviewed Original ResearchConceptsER-positive DCISMagnetic resonance imagingPreoperative letrozoleEndocrine therapyDuctal carcinomaInvasive cancerH-scorePhase II single-arm studyExtended endocrine therapyMonths of letrozolePrimary endocrine therapyPrimary nonoperative treatmentPrimary end pointBreast magnetic resonance imagingCooperative group trialsSingle-arm studyER H-scoreShort-term coursePositive DCISNonoperative treatmentPostmenopausal patientsPostmenopausal womenFuture trialsStudy protocolBiomarker changes
2019
Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study
Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RL, Freedman RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clinical Cancer Research 2019, 25: 5398-5406. PMID: 31018921, DOI: 10.1158/1078-0432.ccr-18-3143.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCell ProliferationExerciseExercise TherapyFemaleHumansPreoperative CareConceptsPre-operative healthBreast cancerExercise interventionKi-67Exercise participantsLower cancer-specific mortalityPre-operative exercise interventionCancer-specific mortalityControl participantsBody mass indexTumor immune infiltratesImpact of exerciseBreast cancer proliferationMinutes/weekBreast cancer diagnosisOpportunity trialBaseline biopsiesImmune infiltratesMass indexSurgical excisionMean ageIntervention periodGene expressionChanges of expressionBreast tumors
2014
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Medicine 2014, 3: 293-299. PMID: 24464780, PMCID: PMC3987079, DOI: 10.1002/cam4.164.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerPathological complete responsePositive breast cancerBreast cancerPreoperative capecitabineClinical responseHER2-negative operable breast cancerDihydropyrimidine dehydrogenaseOnly grade 3 toxicityOverall clinical response rateThymidine phosphorylaseGrade 3 responsePartial clinical responsePathological response assessmentsPreoperative chemotherapy regimensClinical response rateComplete clinical responseGrade 3 toxicityOperable breast cancerPhase II studyPalmar-plantar erythrodysesthesiaMetastatic breast cancerTime of surgeryMiller-Payne
2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research And Treatment 2012, 136: 919-926. PMID: 23143284, DOI: 10.1007/s10549-012-2333-9.Peer-Reviewed Original ResearchConceptsPreoperative systemic therapyCore needle biopsyMulti-gene signatureSystemic therapyConsensus conferenceHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Fine needle aspiration cytologyEarly breast cancerGrowth factor receptor 2Node-positive casesLikelihood of patientsIndividualized treatment regimensKi67 labeling indexNeedle aspiration cytologyFactor receptor 2Treatment-induced changesCell proliferative activityLymph node diagnosisAxillary surgeryLocoregional managementNodal statusLocal therapySurgical treatmentTreatment algorithm
2008
Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions
Gralow JR, Zujewski JA, Winer E. Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions. Journal Of Clinical Oncology 2008, 26: 696-697. PMID: 18258975, DOI: 10.1200/jco.2007.15.9459.Peer-Reviewed Original ResearchPreoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. Journal Of Clinical Oncology 2008, 26: 814-819. PMID: 18258991, DOI: 10.1200/jco.2007.15.3510.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsCongresses as TopicFemaleHumansMastectomy, SegmentalNational Cancer Institute (U.S.)Neoadjuvant TherapyNeoplasm, ResidualPatient Care TeamPatient SelectionPreoperative CareReceptor, ErbB-2Remission InductionUnited StatesConceptsOperable breast cancerPreoperative systemic therapyBreast conservation ratesSystemic therapyInvasive breast cancerBreast cancerTumor responsePreoperative therapyPathologic assessmentNational Cancer Institute StatePostoperative adjuvant systemic therapyInitial tumor responseAdjuvant systemic therapyPathologic complete responseSurrogate end pointsStandard of careMultimodality treatment programBreast cancer biologyAdjuvant settingOperable diseaseOverall survivalPreoperative chemotherapySystemic treatmentComplete responseLymph nodes
2007
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. Clinical Cancer Research 2007, 13: 1198-1207. PMID: 17317830, DOI: 10.1158/1078-0432.ccr-06-1304.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleGenes, erbB-2HumansMalePredictive Value of TestsPreoperative CareReceptor, ErbB-2TrastuzumabVinblastineVinorelbineConceptsPathologic complete responsePreoperative trastuzumabBreast cancerClinical responseComplete responseStage II/III breast cancerHER2-positive early breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Clinical complete responseEarly breast cancerGrowth factor receptor 2Estrogen receptor statusPositive breast cancerPredictors of responseBasal-like phenotypeInsulin-like growthFactor receptor 2Predictors of resistanceReceptor membrane expressionExtremes of responseGrowth factor pathwaysLow response rateGrowth factor receptorPreoperative treatment